115 results
Page 3 of 6
8-K
EX-99.1
xvd87ezst2
11 Feb 21
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
8ur3f9pnp346o9
11 Jan 21
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
8:06am
8-K
EX-99.1
3gpm9
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
4hq mpqpbka6r58pr
25 Sep 20
Departure of Directors or Certain Officers
9:22am
8-K
EX-10.1
kevfkxhvcecblg
25 Sep 20
Departure of Directors or Certain Officers
9:22am
8-K
EX-10.2
n9dfwq omr9yued88bvy
25 Sep 20
Departure of Directors or Certain Officers
9:22am
8-K
EX-99.1
kbyxhtqqc7p9c 2dw57u
4 Aug 20
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
344f6y6iuuriq
14 Jul 20
Karyopharm Announces Preliminary Unaudited Second Quarter
7:08am
424B5
ogfco1euwexmu
5 May 20
Prospectus supplement for primary offering
5:05pm
8-K
EX-1.1
33witzodt1dfao1 64
4 Mar 20
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
4:22pm
424B5
l9d6gb5e
4 Mar 20
Prospectus supplement for primary offering
4:15pm
424B5
1gjy8e9dx xj2vwsvu
2 Mar 20
Prospectus supplement for primary offering
4:21pm
8-K
EX-99.1
dqfkpnavrf 5tc3o6
13 Feb 20
Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
7:09am
8-K
EX-99.1
mi4 xlxhjw
13 Jan 20
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update
7:12am